Sagimet Biosciences Inc. (SGMT) News
Track canonical SquawkNews coverage tagged to SGMT, Sagimet Biosciences Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. NASDAQ:SGMT, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathwa
GEOPOLITICS | Sep 28, 2026, 11:08 AM UTC
L
Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:07 PM UTC
L
SGMT: Denifanstat's phase III acne trial launches soon, aiming for rapid market entry and long exclusivity
Denifanstat, a novel oral FASN inhibitor, is advancing to a US phase III acne trial with strong efficacy and safety data, targeting a large unmet need. Premium pricing and broad payer support are anticipated, with patent
EQUITY | Sep 09, 2026, 07:51 PM UTC
L
Barclays raises Sagimet Biosciences price target to $18
Barclays raised its Sagimet Biosciences price target to $18.00 a share from $8.00, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 01:20 PM UTC
L
Cantor Fitzgerald initiates Sagimet Biosciences with Overweight rating
Cantor Fitzgerald initiated Sagimet Biosciences with an Overweight rating and announced a $10.71/share price target.
EQUITY | Sep 09, 2026, 11:16 AM UTC
L
Sagimet Biosciences to participate in two upcoming investor conferences
Sagimet Biosciences said management will participate in two upcoming investor conferences, according to the company’s announcement.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
SGMT - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
SGMT - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:00 AM UTC
L
Sagimet Biosciences advances AURORA U.S. Phase 3 denifanstat trial
Sagimet Biosciences advances its AURORA U.S. Phase 3 trial of denifanstat in acne toward patient enrollment in Q4 2026.
EQUITY | Aug 25, 2026, 11:00 AM UTC
L
Sagimet Biosciences announces Nasdaq inducement grant under Rule 5635(c)(4)
Sagimet Biosciences (SGMT) announces an inducement grant under Nasdaq Listing Rule 5635(c)(4), with the filing details not provided in the alert.
EQUITY | Aug 17, 2026, 08:28 PM UTC
H
Sagimet Biosciences gets FDA “Study May Proceed” letter for Phase 3
Sagimet Biosciences (SGMT) says the FDA issued a “Study May Proceed” letter and IND clearance for a Phase 3 trial in acne in adolescent and adult patients.
EQUITY | Aug 13, 2026, 11:01 AM UTC